A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
Authors: Dasyam Nathaniel , Sharples Katrina J. , Barrow Catherine , Huang Ying , Bauer Evelyn , Mester Brigitta , Wood Catherine E. , Authier-Hall Astrid , Dzhelali Marina , Ostapowicz Tess , Kumar Rajiv , Lowe Jessica , Maxwell Alice , Burn Olivia K. , Williams Geoffrey M. , Carley Sarah E. , Caygill Graham , Jones Jeremy , Chan Susanna T. S. , Hinder Victoria A. , Macapagal Jerome , McCusker Monica , Weinkove Robert , Brimble Margaret A. , Painter Gavin F. , Findlay Michael P. , Dunbar P. Rod , Gasser Olivier , Hermans Ian F. 
Published: March 2023

Aim

We have previously reported that polyfunctional T cell responses can be induced to the cancer testis antigen NY-ESO-1 in melanoma patients injected with mature autologous monocyte-derived dendritic cells (DCs) loaded with long NY-ESO-1-derived peptides together withα-galactosylceramide (α-GalCer), an agonist for type 1 Natural Killer T (NKT) cells.

Objective

To assess whether inclusion ofα-GalCer in autologous NY-ESO-1 long peptide-pulsed DC vaccines (DCV + α-GalCer) improves T cell responses when compared to peptide-pulsed DC vaccines withoutα-GalCer (DCV).

Design, setting and participants

Single-centre blinded randomised controlled trial in patients ≥ 18 years old with histologically confirmed, fully resected stage II–IV malignant cutaneous melanoma, conducted between July 2015 and June 2018 at the Wellington Blood and Cancer Centre of the Capital and Coast District Health Board.

Interventions

Stage I. Patients were randomised to two cycles of DCV or DCV + α-GalCer (intravenous dose of 10 × 106cells, interval of 28 days).Stage II.Patients assigned to DCV + α-GalCer were randomised to two further cycles of DCV + α-GalCer or observation, while patients initially assigned to DCV crossed over to two cycles of DCV + α-GalCer.

Outcome measures

Primary:Area under the curve (AUC) of mean NY-ESO-1-specific T cell count detected by ex vivo IFN-γ ELISpot in pre- and post-treatment blood samples, compared between treatment arms at Stage I.Secondary:Proportion of responders in each arm at Stage I; NKT cell count in each arm at Stage I; serum cytokine levels at Stage I; adverse events Stage I; T cell count for DCV + α-GalCer versus observation at Stage II, T cell count before versus after cross-over.

Results

Thirty-eight patients gave written informed consent; 5 were excluded before randomisation due to progressive disease or incomplete leukapheresis, 17 were assigned to DCV, and 16 to DCV + α-GalCer. The vaccines were well tolerated and associated with increases in mean total T cell count, predominantly CD4+T cells, but the difference between the treatment arms was not statistically significant (difference − 6.85, 95% confidence interval, − 21.65 to 7.92;P = 0.36). No significant improvements in T cell response were associated with DCV + α-GalCer with increased dosing, or in the cross-over. However, the NKT cell response toα-GalCer-loaded vaccines was limited compared to previous studies, with mean circulating NKT cell levels not significantly increased in the DCV + α-GalCer arm and no significant differences in cytokine response between the treatment arms.

Conclusions

A high population coverage of NY-ESO-1-specific T cell responses was achieved with a good safety profile, but we failed to demonstrate that loading withα-GalCer provided an additional advantage to the T cell response with this cellular vaccine design. Clinical trial registration: ACTRN12612001101875. Funded by the Health Research Council of New Zealand.